Ganli Pharmaceutical: The company has obtained GMP certification from the National Health Surveillance Agency of Brazil.

Ganli Pharmaceutical announced that its subsidiary, Ganli Pharmaceutical Brazil Trade and Pharmaceutical Import Limited, has received the Drug Production Quality Management Standard Certification Certificate issued by the National Health Surveillance Agency of Brazil. The drug names are Insulin Aspart Raw Material and Insulin Lispro Raw Material, with certification number 1734405/24-4, valid until March 23, 2028. Insulin Lispro and Insulin Aspart are both rapid-acting insulin analogs with the characteristics of rapid onset and short duration of action, which can effectively control postprandial blood sugar fluctuations and reduce the risk of hypoglycemia before meals.